From Our Partners
Monday, June 27, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Inovio Initiates Clinical Trial for Ebola DNA Immunotherapies

by Global Biodefense Staff
May 13, 2015
Universal Influenza Vaccine Research

Inovio Pharmaceuticals, Inc. this week announced that the company has initiated a phase I trial to evaluate safety, tolerability and immune responses of Inovio’s DNA immunotherapy for Ebola.

In previously published preclinical testing, Inovio’s DNA-based Ebola immunotherapy protected 100% of immunized animals from death and sickness after being exposed to a lethal dose of the Ebola virus.

This is the first step in the Inovio-led consortium selected by the U.S. Defense Advanced Research Projects Agency (DARPA) to take a multi-faceted approach to develop products to both prevent and treat Ebola infection. These programs include development and early clinical testing of:

  • Inovio’s DNA-based vaccine against Ebola, for which the first study was initiated this week.
  • Inovio’s therapeutic DNA-based monoclonal antibody product dMAb against Ebola virus infection. This promising new technology has properties that are best suited to respond to an Ebola outbreak in that they could be designed and manufactured expediently on a large scale using proven fermentation technology, are thermal-stable, and may provide more rapid therapeutic benefit.
  • A highly potent conventional protein-based therapeutic monoclonal antibody (mAb) product against Ebola virus infection.

This initial trial will evaluate Inovio’s Ebola immunotherapy (INO-4212) in five groups of healthy subjects receiving INO-4212 and its components (INO-4201 and INO-4202) alone or in combination with INO-9012, delivered into muscle or skin using Inovio’s proprietary DNA delivery technology.

“The Inovio-led partnership is uniquely positioned to create and test methods to both prevent and treat Ebola virus infections,” said Dr. J. Joseph Kim, President and CEO. “The global product development experts we have brought together coupled with Inovio’s DNA-based vaccines and immunotherapies should meet and exceed the expected outcomes. Demonstrating our commitment and speed, we have begun our first trial just a few weeks after being selected by DARPA to advance this promising program.”

From Our Partners
Tags: AntiviralsDARPAEbola

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC